Présentation de l'entreprise
Apollomics, Inc. operates within the healthcare sector as a clinical-stage biopharmaceutical company dedicated to the discovery and development of oncology therapies designed to harness the immune system and target specific molecular pathways for cancer inhibition. The company's product portfolio features Vebreltinib (APL-101), an oral active compound intended for therapeutic application. This entity functions within the biotechnology industry, a segment characterized by high research and development expenditures and significant regulatory hurdles before product commercialization. As of the latest data, Apollomics, Inc. maintains a market capitalization of $33.07 million and reports annual revenue of $6.93 million, supported by a workforce of 13 employees. These valuation and revenue figures indicate that the company is a micro-cap entity with a limited operational scale, suggesting that its financial resources are heavily concentrated in early-stage development rather than established commercial operations. The small employee count relative to the revenue generated by the TTM figures further highlights the asset-light nature of its current business model, which relies heavily on intellectual property and external partnerships rather than a large internal sales force.
Santé financière
The company reports revenue of $6.93 million over the trailing twelve months, yet it simultaneously records a net income of -$31,188,000 and an EBITDA of -$26,359,000, revealing a substantial gap where operating costs and development expenses significantly exceed revenue generation. This negative net income relative to positive revenue indicates that the cost structure is driven primarily by R&D investments and general administrative expenses typical of clinical-stage firms, resulting in a net loss despite sales activity. The free cash flow stands at -$14,440,000, which signifies that the company is burning cash to fund its operations and development pipeline, thereby limiting its immediate financial flexibility without external capital injections. Margin analysis shows a gross margin of 100.0%, reflecting the absence of cost of goods sold in the current operational phase, while the operating margin of -124.8% and profit margin of 0.0% demonstrate that overhead costs are consuming all revenue and then some. On the balance sheet, the company holds $2.10 million in cash against $744,000 in debt, resulting in a debt-to-equity ratio of N/A, which suggests the company is currently unleveraged but operates with a negative equity base. The current ratio of 0.97 indicates that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity constraints. Return on Equity is reported at -380.1% and Return on Assets at -72.3%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns in the current fiscal period.
Évaluation de la valorisation
Valuation metrics for Apollomics, Inc. present a complex picture, with a P/E Ratio (TTM) of N/A and a forward P/E of -23.69, implying that the market does not yet anticipate positive earnings in the near term due to the company's ongoing losses. The price-to-book ratio is listed at -3.86, a figure that typically indicates the company's book value is negative, often due to accumulated losses exceeding retained earnings, and prevents standard valuation comparisons based on tangible asset backing. Alternative valuation measures such as the price-to-sales ratio of 4.77 and an EV/EBITDA of -0.59 suggest that the market is pricing the company primarily on its future potential rather than current profitability or asset base. Price action over the last year shows a 52-week high of $42.12 and a 52-week low of $3.66, placing the current trading price significantly below the recent high and within a highly volatile trading range. The stock exhibits a beta of 1.83, indicating that its price volatility is substantially higher than the broader market, moving with greater intensity during periods of market stress or rally. These valuation dynamics reflect the high-risk profile of a biotech firm where investors are betting on future clinical successes rather than current financial fundamentals.
Growth & Income
Revenue growth for the trailing twelve months is recorded at 380.8%, while earnings growth is N/A, indicating that the company is expanding its top line rapidly but has not yet achieved profitability to measure earnings expansion. The divergence between the massive revenue increase and the lack of earnings growth implies that the new revenue is being consumed by even higher development costs, maintaining the company in a loss-making state. As a non-dividend payer, Apollomics, Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all generated cash to reinvest into its research and development activities rather than distributing income to shareholders. The overall growth and income profile is defined by aggressive top-line expansion coupled with a complete absence of current income generation, a common trajectory for clinical-stage biopharmaceutical companies relying on future regulatory approvals and commercialization to unlock value.